High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors

Human Pathology

Volumn 45, Issue 3, 2014, Pages 573-582

  Künstlinger, Helen ^a   Binot, Elke ^a   Merkelbach Bruse, Sabine ^a   Huss, Sebastian ^a,b   Wardelmann, Eva ^a,b   Buettner, Reinhard ^a   Schildhaus, Hans Ulrich ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Gastrointestinal stromal tumor; GIST; High resolution melting; Imatinib; PDGFRA

Indexed keywords

GASTROINTESTINAL STROMAL TUMOR; GIST; HIGH-RESOLUTION MELTING; IMATINIB; PDGFRA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEIC ACID DENATURATION; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84894069017     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.10.025     Document Type: Article

References (46)

1. H.U. Schildhaus, S. Merkelbach-Bruse, R. Buttner, and E. Wardelmann Pathology and molecular biology of gastrointestinal stromal tumors (GIST) Radiologe 49 2009 1104 1108
2. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii49 vii55
3. M. von Mehren, R.S. Benjamin, and M.M. Bui et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw 10 2012 951 960
4. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2006 70 83
5. E. Wardelmann, A. Hrychyk, and S. Merkelbach-Bruse et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors J Mol Diagn 6 2004 197 204
6. J. Lasota, and M. Miettinen Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours Histopathology 53 2008 245 266
7. S. Huss, H. Kunstlinger, and E. Wardelmann et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del) Mod Pathol 26 2013 1004 1012
8. C.L. Corless, A. Schroeder, and D. Griffith et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 2005 5357 5364
9. P.A. Cassier, E. Fumagalli, and P. Rutkowski et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era Clin Cancer Res 18 2012 4458 4464
10. S. Merkelbach-Bruse, W. Dietmaier, and L. Fuzesi et al. Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors BMC Med Genet 11 2010 106
11. S. Huss, E. Wardelmann, and D. Goltz et al. Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization Histopathology 61 2012 59 68
12. H. Künstlinger, S. Huss, and S. Merkelbach-Bruse et al. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high resolution melting assay for mutational testing Am J Surg Pathol 2013 In press
13. Y. Takazawa, S. Sakurai, and Y. Sakuma et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease) Am J Surg Pathol 29 2005 755 763
14. C. Bai, X. Liu, and J.M. Zheng et al. A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro Oncol Lett 3 2012 1139 1143
15. A. Chou, J. Chen, and A. Clarkson et al. Succinate dehydrogenase- deficient GISTs are characterized by IGF1R overexpression Mod Pathol 25 2012 1307 1313
16. Y.N. Xiang, D.X. Gao, H.Y. He, Y.P. Wang, W. Zhang, and J. Zheng Ultrastructural features and platelet-derived growth factor receptor A gene mutations in CD117-negative gastrointestinal stromal tumor Zhonghua Bing Li Xue Za Zhi 35 2006 73 76
17. J. Lasota, A. Dansonka-Mieszkowska, L.H. Sobin, and M. Miettinen A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential Lab Invest 84 2004 874 883
18. M.C. Heinrich, C.L. Corless, and A. Duensing et al. PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708 710
19. A. Kern, H. Gorgens, and D.D. Dittert et al. Mutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary gastrointestinal stromal tumors (GISTs) J Surg Oncol 104 2011 59 65
20. M.C. Heinrich, D. Griffith, and A. McKinley et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res 18 2012 4375 4384
21. T. Liu, C. Willmore-Payne, L.J. Layfield, R.E. Glasgow, and J.A. Holden A gastrointestinal stromal tumor of the stomach morphologically resembling a neurofibroma: demonstration of a novel platelet-derived growth factor receptor alpha exon 18 mutation Hum Pathol 39 2008 1849 1853
22. S. Huss, J. Nehles, and E. Binot et al. beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis Histopathology 62 2013 294 304
23. G.H. Kang, A. Srivastava, and Y.E. Kim et al. DOG1 and PKC-theta are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors Mod Pathol 24 2011 866 875
24. M. Kuroiwa, M. Hiwatari, and J. Hirato et al. Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA J Pediatr Surg 40 2005 1798 1801
25. A.T. de Oliveira, R.M. Reis, and J. Afonso et al. Lymphangiogenic VEGF-C and VEGFR-3 expression in genetically characterised gastrointestinal stromal tumours Histol Histopathol 26 2011 1499 1507
26. S. Rossi, D. Gasparotto, and L. Toffolatti et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size Am J Surg Pathol 34 2010 1480 1491
27. H.M. Chang, M.H. Ryu, and H. Lee et al. PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors Oncology 74 2008 88 95
28. J.E. Kwon, H.J. Kang, and S.H. Kim et al. Pathological characteristics of gastrointestinal stromal tumours with PDGFRA mutations Pathology 41 2009 544 554
29. F. Haller, B. Gunawan, and A. von Heydebreck et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors Clin Cancer Res 11 2005 6589 6597
30. F. Haller, N. Happel, and H.J. Schulten et al. Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors Mod Pathol 20 2007 1103 1111
31. N. Theou, S. Tabone, and R. Saffroy et al. High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors Biochim Biophys Acta 1688 2004 250 256
32. P. Origone, S. Gargiulo, and L. Mastracci et al. Molecular characterization of an Italian series of sporadic GISTs Gastric Cancer 16 2013 596 601
33. M. Daniels, I. Lurkin, and R. Pauli et al. Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST) Cancer Lett 312 2011 43 54
34. J. Ostrowski, M. Polkowski, and A. Paziewska et al. Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression BMC Cancer 9 2009 413
35. O. Daum, P. Grossmann, T. Vanecek, R. Sima, P. Mukensnabl, and M. Michal Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histological analysis of 60 cases of gastric gastrointestinal stromal tumors Ann Diagn Pathol 11 2007 27 33
36. S. Calabuig-Farinas, J.A. Lopez-Guerrero, and S. Navarro et al. Evaluation of prognostic factors and their capacity to predict biological behavior in gastrointestinal stromal tumors Int J Surg Pathol 19 2011 448 461
37. M. Debiec-Rychter, R. Sciot, and A. Le Cesne et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 2006 1093 1103
38. Y. Murayama, M. Yamamoto, and R. Iwasaki et al. Greater omentum gastrointestinal stromal tumor with PDGFRA-mutation and hemoperitoneum World J Gastrointest Oncol 4 2012 119 124
39. S. Zheng, L.R. Chen, H.J. Wang, and S.Z. Chen Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor Hepatogastroenterology 54 2007 2285 2290
40. J.A. Fletcher Role of KIT and platelet-derived growth factor receptors as oncoproteins Semin Oncol 31 2004 4 11
41. H.U. Schildhaus, T. Cavlar, E. Binot, R. Buttner, E. Wardelmann, and S. Merkelbach-Bruse Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene J Pathol 216 2008 176 182
42. J. Lasota, and M. Miettinen KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs) Semin Diagn Pathol 23 2006 91 102
43. A. Wozniak, P. Rutkowski, and A. Piskorz et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience Ann Oncol 23 2012 353 360
44. F.A. Monzon, S. Ogino, M.E. Hammond, K.C. Halling, K.J. Bloom, and M.N. Nikiforova The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer Arch Pathol Lab Med 133 2009 1600 1606
45. H. Joensuu Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management Drugs 72 2012 1953 1963
46. P. Rutkowski, E. Bylina, and A. Klimczak et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study BMC Cancer 12 2012 107